VDPHL

This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA).
AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness.
This single center, open-label, study will last about 6 months and includes 7 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6). Male subjects that meet the study eligibility criteria will be administered VDPHL01 twice daily for 6 months.